Ipsen Biopharmaceuticals

Ipsen is a global biopharmaceutical company focused on specialty medicines in three areas: oncology, rare disease and neuroscience. Its Cambridge presence places it in the Kendall Square life sciences cluster. The company concentrates on conditions with high unmet medical need, from cancers of the kidney, liver, pancreas, prostate and breast to neuroendocrine tumors, rare bone, growth and liver disorders, and spasticity, which it treats with its botulinum toxin Dysport.

Headquartered in France, Ipsen has more than 5,000 employees worldwide and has worked in oncology since 1986. Its strategy, called Focus. Together. For patients & society, emphasizes patient access, a sustainable pipeline and partnerships with biotechs and academic groups, with a goal of delivering at least one new molecular entity or meaningful indication each year. Recent moves include acquiring Kartos Therapeutics and Memo Therapeutics, and new data for IQIRVO in the liver disease PBC.

What to Know

• The company aims to be a leading global mid-size biopharmaceutical company.
• Ipsen ran the first head-to-head study comparing Dysport and Botox in adults.
• It works directly with patient organizations to shape research and access programs.
• It is a member of the Kendall Square Association.